1. Home
  2. PD vs ABUS Comparison

PD vs ABUS Comparison

Compare PD & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PagerDuty Inc.

PD

PagerDuty Inc.

HOLD

Current Price

$10.03

Market Cap

782.0M

Sector

Technology

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.73

Market Cap

839.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PD
ABUS
Founded
2009
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
782.0M
839.5M
IPO Year
2019
2008

Fundamental Metrics

Financial Performance
Metric
PD
ABUS
Price
$10.03
$4.73
Analyst Decision
Buy
Strong Buy
Analyst Count
9
1
Target Price
$12.63
$5.00
AVG Volume (30 Days)
2.1M
2.3M
Earning Date
05-28-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
416.95
55.26
EPS
0.13
0.87
Revenue
$492,546,000.00
$14,083,000.00
Revenue This Year
$3.58
N/A
Revenue Next Year
$2.88
$239.71
P/E Ratio
$74.23
$5.52
Revenue Growth
5.36
128.21
52 Week Low
$5.70
$3.08
52 Week High
$17.45
$5.10

Technical Indicators

Market Signals
Indicator
PD
ABUS
Relative Strength Index (RSI) 67.77 64.91
Support Level $6.08 $4.15
Resistance Level $10.70 $4.85
Average True Range (ATR) 0.45 0.18
MACD 0.06 0.05
Stochastic Oscillator 90.97 85.54

Price Performance

Historical Comparison
PD
ABUS

About PD PagerDuty Inc.

PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the company derives a majority of its revenue from the United States and the rest from International markets.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: